Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Data
2.3. Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. DAPSA Response
3.3. Predictors of DAPSA Low Disease Activity or Remission at 6 and 12 Months
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Coates, L.C.; Helliwell, P.S. Psoriatic Arthritis: State of the Art Review. Clin. Med. 2017, 17, 65–70. [Google Scholar] [CrossRef]
- Gossec, L.; Smolen, J.S.; Ramiro, S.; de Wit, M.; Cutolo, M.; Dougados, M.; Emery, P.; Landewé, R.; Oliver, S.; Aletaha, D.; et al. European League Against Rheumatism (EULAR) Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2015 Update. Ann. Rheum. Dis. 2016, 75, 499–510. [Google Scholar] [CrossRef] [PubMed]
- Kavanaugh, A.; Mease, P.J.; Gomez-Reino, J.J.; Adebajo, A.O.; Wollenhaupt, J.; Gladman, D.D.; Lespessailles, E.; Hall, S.; Hochfeld, M.; Hu, C.; et al. Treatment of Psoriatic Arthritis in a Phase 3 Randomised, Placebo-Controlled Trial with Apremilast, an Oral Phosphodiesterase 4 Inhibitor. Ann. Rheum. Dis. 2014, 73, 1020–1026. [Google Scholar] [CrossRef] [PubMed]
- Cutolo, M.; Myerson, G.E.; Fleischmann, R.M.; Lioté, F.; Díaz-González, F.; Van den Bosch, F.; Marzo-Ortega, H.; Feist, E.; Shah, K.; Hu, C.; et al. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. J. Rheumatol. 2016, 43, 1724–1734. [Google Scholar] [CrossRef] [PubMed]
- Wells, A.F.; Edwards, C.J.; Kivitz, A.J.; Bird, P.; Nguyen, D.; Paris, M.; Teng, L.; Aelion, J.A. Apremilast Monotherapy in DMARD-Naive Psoriatic Arthritis Patients: Results of the Randomized, Placebo-Controlled PALACE 4 Trial. Rheumatology 2018, 57, 1253–1263. [Google Scholar] [CrossRef] [PubMed]
- Edwards, C.J.; Blanco, F.J.; Crowley, J.; Birbara, C.A.; Jaworski, J.; Aelion, J.; Stevens, R.M.; Vessey, A.; Zhan, X.; Bird, P. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement: A Phase III, Randomised, Controlled Trial (PALACE 3). Ann. Rheum. Dis. 2016, 75, 1065–1073. [Google Scholar] [CrossRef] [PubMed]
- Mease, P.J.; Gladman, D.D.; Ogdie, A.; Coates, L.C.; Behrens, F.; Kavanaugh, A.; McInnes, I.; Queiro, R.; Guerette, B.; Brunori, M.; et al. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. Arthritis Care Res. 2020, 72, 814–821. [Google Scholar] [CrossRef] [PubMed]
- Mease, P.J.; Kavanaugh, A.; Ogdie, A.; Wells, A.F.; Bergman, M.; Gladman, D.D.; Richter, S.; Teng, L.; Jardon, S.; Smolen, J.S. Baseline Disease Activity Predicts Achievement of CDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-Naïve Patients With Psoriatic Arthritis. J. Rheumatol. 2022, 49, 694–699. [Google Scholar] [CrossRef] [PubMed]
- Wolfe, F. Why Results of Clinical Trials and Observational Studies of Antitumour Necrosis Factor (Anti-TNF) Therapy Differ: Methodological and Interpretive Issues. Ann. Rheum. Dis. 2004, 63, ii13–ii17. [Google Scholar] [CrossRef] [PubMed]
- Favalli, E.G.; Conti, F.; Selmi, C.; Iannone, F.; Bucci, R.; D’Onofrio, F.; Carlino, G.; Santo, L.; Semeraro, A.; Zuccaro, C.; et al. Retrospective Evaluation of Patient Profiling and Effectiveness of Apremilast in an Italian Multicentric Cohort of Psoriatic Arthritis Patients. Clin. Exp. Rheumatol. 2020, 38, 19–26. [Google Scholar] [PubMed]
- Ceccarelli, F.; Lucchetti, R.; Perricone, C.; Spinelli, F.R.; Cipriano, E.; Truglia, S.; Miranda, F.; Riccieri, V.; Di Franco, M.; Scrivo, R.; et al. Musculoskeletal Ultrasound in Monitoring Response to Apremilast in Psoriatic Arthritis Patients: Results from a Longitudinal Study. Clin. Rheumatol. 2019, 38, 3145–3151. [Google Scholar] [CrossRef] [PubMed]
- Abignano, G.; Fadl, N.; Merashli, M.; Wenham, C.; Freeston, J.; McGonagle, D.; Marzo-Ortega, H. Apremilast for the Treatment of Active Psoriatic Arthritis: A Single-Centre Real-Life Experience. Rheumatology 2018, 57, 578–580. [Google Scholar] [CrossRef] [PubMed]
- de Vlam, K.; Toukap, A.N.; Kaiser, M.-J.; Vanhoof, J.; Remans, P.; Van den Berghe, M.; Di Romana, S.; Van den Bosch, F.; Lories, R. Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study. Adv. Ther. 2022, 39, 1055–1067. [Google Scholar] [CrossRef] [PubMed]
- Ogdie, A.; Liu, M.; Glynn, M.; Emeanuru, K.; Harrold, L.R.; Richter, S.; Guerette, B.; Mease, P.J. Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. J. Rheumatol. 2021, 48, 693–697. [Google Scholar] [CrossRef] [PubMed]
- Ariani, A.; Parisi, S.; Del Medico, P.; Farina, A.; Visalli, E.; Molica Colella, A.B.; Lumetti, F.; Caccavale, R.; Scolieri, P.; Andracco, R.; et al. Apremilast Retention Rate in Clinical Practice: Observations from an Italian Multi-Center Study. Clin. Rheumatol. 2022, 41, 3219–3225. [Google Scholar] [CrossRef] [PubMed]
- Taylor, W.; Gladman, D.; Helliwell, P.; Marchesoni, A.; Mease, P.; Mielants, H. CASPAR Study Group Classification Criteria for Psoriatic Arthritis: Development of New Criteria from a Large International Study. Arthritis Rheum. 2006, 54, 2665–2673. [Google Scholar] [CrossRef] [PubMed]
- Schoels, M.; Aletaha, D.; Funovits, J.; Kavanaugh, A.; Baker, D.; Smolen, J.S. Application of the DAREA/DAPSA Score for Assessment of Disease Activity in Psoriatic Arthritis. Ann. Rheum. Dis. 2010, 69, 1441–1447. [Google Scholar] [CrossRef] [PubMed]
Total Cohort | PLG | RWG | ||
---|---|---|---|---|
n | 293 | 54 | 239 | |
M:F | 126:167 | 21:33 | 105:134 | |
Age, median (IQR), yrs | 60 (53–68) | 61 (52.5–67) | 60 (53–68) | |
Smokers: yes/former/no * | 46:37:208 | 10:9:35 | 36:28:173 | |
BMI, median (IQR), kg/m2 ** | 26 (23.7–29.4) | 25.9 (23.5–29.7) | 26.1 (23.8–29.3) | |
PsA duration, median (IQR), months | 49 (17–98.25) | 23 (13–65) | 53 (20–101.5) | |
PsA phenotype | Oligo-articular Poli-articular Enthesitic Dactylitis Axial | 164 129 144 101 36 | 26 28 23 18 7 | 138 101 121 83 29 |
SJC, median (IQR) | 3 (2–4) | 4 (3–6) | 2 (2–4) | |
TJC, median (IQR) | 6 (3–10) | 6 (4–12) | 6 (3–9) | |
LEI, median (IQR) | 0 (0–2) | 0 (0–2) | 0 (0–2) | |
Dactylitis, median (IQR), fingers | 0 (0–1) | 0 (0–0) | 0 (0–1) | |
CRP, median (IQR), mg/dL | 2.0 (0.7–4.6) | 2.5 (1.0–5.2) | 1.9 (0.6–4.2) | |
DAPSA, median (IQR) | 24.4 (19.4–32) | 28.7 (23.1–36.9) | 24 (18.5–31) | |
Prior csDMARDs use, n | MTX LFN SSZ CYA | 188 50 76 27 | 32 8 14 1 | 156 42 62 26 |
Prior bDMARDs use, n | TNFi IL17i IL12/IL23i Abatacept | 81 21 20 2 | 0 0 0 0 | 81 21 20 2 |
Concomitant csDMARDs, n | 58 | 10 | 48 | |
Concomitant relevant disease, n | Cancer HCV/HBV Latent TB Other infections | 89 16 17 20 | 0 0 0 3 | 89 16 17 17 |
Univariate Analysis | Multivariate Analysis | |||||
---|---|---|---|---|---|---|
Variable | OR | 95% CI | p | OR | 95% CI | p |
Age | 0.988 | 0.969–1.007 | 0.943 | |||
Smoke | 1.226 | 0.646–2.325 | 0.533 | |||
Sex | 1.136 | 0.712–1.813 | 0.592 | |||
BMI | 0.985 | 0.934–1.039 | 0.583 | |||
Relevant comorbidity | 1.22 | 0.767–1.941 | 0.4 | |||
Disease duration | 1 | 0.997–1.004 | 0.87 | |||
Baseline DAPSA | 0.837 | 0.8–0.876 | <0.0001 | 0.841 | 0.804–0.879 | <0.0001 |
Concomitant csDMARD | 0.652 | 0.358–1.187 | 0.161 | |||
Number of previous bDMARD | 0.718 | 0.578–0.893 | 0.0029 | 0.777 | 0.604–1.0003 | 0.0502 |
Number of previous csDMARD | 1.173 | 0.909–1.512 | 0.219 |
Univariate Analysis | Multivariate Analysis | |||||
---|---|---|---|---|---|---|
Variable | OR | 95% CI | p | OR | 95% CI | p |
Age | 0.999 | 0.98–1.018 | 0.906 | |||
Smoke | 1.181 | 0.621–2.247 | 0.613 | |||
Sex | 1.309 | 0.820–2.087 | 0.259 | |||
BMI | 0.980 | 0.929–1.033 | 0.457 | |||
Relevant comorbidity | 1.299 | 0.818–2.064 | 0.267 | |||
Disease duration | 1.002 | 0.998–1.006 | 0.289 | |||
Baseline DAPSA | 0.908 | 0.881–0.937 | <0.0001 | 0.911 | 0.883–0.939 | <0.0001 |
Concomitant csDMARD | 1.577 | 0.871–2.856 | 0.133 | |||
Number of previous bDMARD | 0.84 | 0.691–1.022 | 0.0815 | 0.856 | 0.691–1.061 | 0.156 |
Number of previous csDMARD | 1.328 | 1.021–1.726 | 0.034 | 1.342 | 1.003–1.795 | 0.048 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Becciolini, A.; Parisi, S.; Del Medico, P.; Farina, A.; Visalli, E.; Molica Colella, A.B.; Lumetti, F.; Caccavale, R.; Scolieri, P.; Andracco, R.; et al. Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study. Biomedicines 2023, 11, 433. https://doi.org/10.3390/biomedicines11020433
Becciolini A, Parisi S, Del Medico P, Farina A, Visalli E, Molica Colella AB, Lumetti F, Caccavale R, Scolieri P, Andracco R, et al. Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study. Biomedicines. 2023; 11(2):433. https://doi.org/10.3390/biomedicines11020433
Chicago/Turabian StyleBecciolini, Andrea, Simone Parisi, Patrizia Del Medico, Antonella Farina, Elisa Visalli, Aldo Biagio Molica Colella, Federica Lumetti, Rosalba Caccavale, Palma Scolieri, Romina Andracco, and et al. 2023. "Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study" Biomedicines 11, no. 2: 433. https://doi.org/10.3390/biomedicines11020433
APA StyleBecciolini, A., Parisi, S., Del Medico, P., Farina, A., Visalli, E., Molica Colella, A. B., Lumetti, F., Caccavale, R., Scolieri, P., Andracco, R., Girelli, F., Bravi, E., Colina, M., Volpe, A., Ianniello, A., Ditto, M. C., Nucera, V., Franchina, V., Platè, I., ... Ariani, A. (2023). Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study. Biomedicines, 11(2), 433. https://doi.org/10.3390/biomedicines11020433